Association between smoking and risk of death in patients with sepsis: A systematic review and meta-analysis

Nai Zhang¹, Yujuan Liu¹, Chuang Yang¹, Peng Zeng¹, Tao Gong¹, Lu Tao¹, Xinai Li²

ABSTRACT

INTRODUCTION Although some research papers have suggested that smoking may increase mortality in patients with sepsis, no evidence has been produced in this regard. This systematic research evaluated the risk of death in patients with sepsis who were smokers to facilitate better clinical decision making. METHODS This is a systematic review registered in PROPERO (CRD42022296654). Searches were conducted to identify suitable studies from the databases of PubMed, Embase, Web of Science and the Cochrane Controlled Register of Trials from January 1980 to June 2021. Two independent reviewers screened the articles using keywords and extracted the data. The Newcastle–Ottawa Scale (NOS) was used to evaluate the quality of evidence. The primary endpoints included the mortality of patients with sepsis. RESULTS Five studies involving 2694 participants were included in our study. Among the five included articles, three studies had an NOS score of 6, while the other two had an NOS score of 7. The results showed that a significantly higher risk of death was observed in smokers with sepsis compared with non-smokers with sepsis (hazard ratio, HR=1.62; 95% CI: 1.11–2.37, p=0.01). Among the patients followed for more than 2 months, the mortality rate of smokers was significantly higher (2.33 times) than that of non-smokers (HR=2.33; 95% CI: 1.83–2.96, p<0.01). The difference in mortality did not reach statistical significance when the follow-up period was shorter than 2 months (HR=1.22; 95% CI: 0.96–1.56, p=0.10). CONCLUSIONS Smoking increased mortality in patients with sepsis when the follow-up period was longer than 2 months.
risk of developing sepsis in COVID-19. In addition, sepsis was associated with a high mortality rate in COVID-19. Furthermore, sepsis was observed more frequently in overweight and obese patients than in those without excess weight or obesity in COVID-19.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes an uncontrolled inflammatory response in patients, with severe new coronary pneumonia characterized by a significant release of pro-inflammatory cytokines, leading to lymphocyte dysfunction and abnormalities of granulocytes and monocytes. Although the treatment of sepsis has developed rapidly in the past few years, the mortality rate from sepsis is still increasing, resulting in a significant burden on all healthcare systems.

Studies have shown that the risk of death is increased in patients with sepsis who are elderly, have a history of cancer, chronic liver disease, acute kidney injury, multiple organ failure and human immunodeficiency virus infection. However, given the complexity of the effects of that, it is difficult to elucidate its true footprint. Some research articles have suggested that smoking may up-regulate inflammatory factors and increase mortality in patients with sepsis. However, no evidence has been produced on the association between smoking and the risk of death in patients with sepsis.

To clarify this argument, we conducted a systematic review using a meta-analysis to compare the mortality rates between smokers and non-smokers in patients with sepsis and assess the mortality-related risk from sepsis among current smokers.

METHODS

Search strategy
This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines (registration information: PROSPERO CRD42022296654). The databases of PubMed, Embase, the Web of Science and the Cochrane Controlled Register of Trials from January 1980 to June 2021 were reviewed. This search was supplemented with a manual screening of retrospective studies. The references were searched manually to identify additional relevant manuscripts using the following keywords: ‘Sepsis’, ‘Bloodstream Infection’, ‘Pyemia’, ‘Septicemia’, ‘Poisoning’, ‘Blood Poisonings’, ‘Severe Sepsis’, ‘Smoking’, ‘Behavior’, ‘Smoking’, ‘death’, ‘mortality rate’ and ‘models, statistical’. Before the final analyses, the search was repeated to identify additional studies.

Selection criteria
The inclusion criteria were as follows: 1) Studies evaluating the mortality in patients with sepsis who smoked, using hazard ratios (HRs), odds ratios (ORs) or relative risk ratios (RRs) with a corresponding 95% confidence interval (CI); and 2) A current smoker was characterized by having smoked at least 100 cigarettes in their lifetime, while non-smokers had smoked less than 100 cigarettes in their lifetime. Sepsis was graded using different versions of the sepsis guidelines, i.e. sepsis version 1, sepsis version 2 and sepsis version 3.

The following were excluded from this systematic review: reviews, letters, comments, studies of pediatric patients, studies of animals, and studies not published in English.

Data extraction
Two investigators independently collected the first author’s name, the study design, the publication year, the study location, the sample size, the smoking habits, the duration of the follow-up and the sepsis events as well as the HRs, ORs and RRs and their associated 95% CIs or standard errors. Any disagreements were resolved through discussion with a third investigator.

Quality assessment
The quality of the included studies was assessed using the Newcastle–Ottawa Scale (NOS). The highest score was 9 points, which was based on three items: comparability (2 points), selection (4 points) and outcome (3 points). Low-quality studies scored <6 points, medium-quality studies scored 6–7 points, and high-quality studies scored 8–9 points.

Statistical analysis
The data on mortality were analyzed using HRs. The inverse-variance weighted random-effects method was used to aggregate the HRs and 95% CIs of all the included studies. The I² test and the chi-squared test were used to assess the heterogeneity across the studies. A fixed-effects model was used in cases of low heterogeneity (I²<50%, or p>0.1). Otherwise, a random-effects model was used. A Galbraith radial
plot was produced to identify the potential causes of heterogeneity, while a Forest plot calculated the aggregated relative risk of death from all studies. A sensitivity analysis was performed to determine whether an individual study had any impact on the aggregated results of the meta-analysis. A funnel plot analysis together with Egger’s test determined publication bias. A meta-regression evaluated potential covariates linked with sepsis. Potential variables between studies that may have had an impact on the results of this research were also evaluated.

Based on these findings, an additional subgroup analysis was conducted to evaluate how these variables impacted the HRs. Statistical analyses were conducted using Stata (version 14.0) software. A p<0.05 was considered statistically significant.

RESULTS
Search results
A total of 1760 relevant studies were initially retrieved. After removing duplicates, 1547 studies were additionally screened. A total of 232 studies were excluded that consisted of meta-analyses, systematic reviews, reviews, case reports and animal experiments. Among the remaining 1315 articles, 1287 studies were excluded after the abstracts were screened. The remaining 28 studies were evaluated, and 23 studies were eventually excluded, 4 of which were letters, commentaries, or editorials; 7 did not report any investigation between smoking and the mortality in sepsis, and the remaining 12 studies did not report risks associated with current smoking and mortality in sepsis (Figure 1). Finally, 5 studies were included in our research. Among the 5 included articles, 3 studies had an NOS score of 6, while the other 2 studies had an NOS score of 7. All studies had an NOS score of 6 or higher, indicating good quality (Table 1).

Characteristics of the selected studies
Five studies involving 2694 participants were included in this research. Among the included studies, four were retrospective, and one was a prospective observational study. The publication dates ranged between 1993 and 2021, and the sample sizes varied from 173 to 1523 participants. The follow-up period varied from 20 days to 6 years. All studies included both genders and clearly defined the current smoking and non-smoking populations.

The meta-analysis of mortality
The result of the heterogeneity test showed moderate to high heterogeneity (I²=74.0%, p=0.004) among the studies (Figure 2). Further analysis using a Galbraith radial plot (Figure 3) revealed a higher possibility of heterogeneity between Pittet et al. and Kempker et al.

Based on the findings of this analysis, we concluded that the evaluated studies had a moderate level of heterogeneity and thus, the random-effects model was
used. As shown in Figure 2, compared with non-smokers, higher mortality was found among the current smokers (HR=1.62; 95% CI: 1.11–2.37). The overall effect (Z) was 2.50 (p=0.01), indicating a significant difference between groups (Figure 2).

**Sensitivity analysis and funnel plot analysis**

The analysis of mortality revealed significant heterogeneity. The sensitivity analysis showed that removing each study did not affect the stability or reliability of the results.

A visual evaluation of the funnel plots revealed a symmetrical distribution (Figure 4). Accordingly, Egger’s regression asymmetry tests showed no significant bias among the studies (p=0.771).

**Meta-regression analysis to evaluate the cause of the heterogeneity**

After evaluating all potential covariables, inconsistencies in the follow-up period between studies were identified as a potential key factor leading to heterogeneity. A meta-regression analysis was performed to confirm this hypothesis. The findings of the meta-regression confirmed that the follow-up period had a significant impact on effect size (p=0.034). Therefore, a further subgroup analysis was performed to investigate how the follow-up period affected mortality.

![Figure 2. Forest plot regarding the risk of death between smokers vs non-smokers with sepsis](image-url)

### Table 1. NOS scores

| Study          | Selection | Comparability | Outcome | NOS score | Definition of sepsis used                                                                 |
|----------------|-----------|---------------|---------|-----------|------------------------------------------------------------------------------------------|
| Pittet 1993    | ★★        | ★★            | ★★      | 6         | Septicemia was defined as a clinical condition associated with one or more positive blood cultures for a commonly accepted pathogen or two or more positive blood cultures for less usual pathogens (coagulate negative staphylococci and candida spp) and either signs of severe infection or evidence of systemic response to severe infection |
| Salive 1993    | ★★        | ★★            | ★★      | 7         | Septicemia was defined as a clinical condition associated with one or more positive blood cultures for a commonly accepted pathogen or two or more positive blood cultures for less usual pathogens (coagulate negative staphylococci and candida spp) and either signs of severe infection or evidence of systemic response to severe infection |

| Study          | Selection | Comparability | Outcome | NOS score | Definition of sepsis used                                                                 |
|----------------|-----------|---------------|---------|-----------|------------------------------------------------------------------------------------------|
| Alroumi 2018   | ★★★       | ★★            | ★       | 6         | The sepsis-2 consensus definitions were utilized                                          |
| Kempker 2018   | ★★        | ★★            | ★★      | 6         | Sepsis is defined as a dysregulated immune response to infection that results in acute organ dysfunction |
| Pehlivanlar 2021 | ★★★★      | ★★            | ★★      | 7         | Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection |
Subgroup meta-analysis

The five studies were divided into two subgroups. Group 1 included studies with a follow-up longer than 2 months, and Group 2 included studies with a follow-up shorter than 2 months.

There was no heterogeneity in the subgroup analysis irrespective of whether the study had a follow-up shorter than two months ($I^2=0\%, p=0.48$) or more than two months ($I^2=0\%, p=0.77$). However, there was moderate heterogeneity ($I^2=74.0\%, p=0.004$) when all studies were analyzed. The above analysis indicated that the follow-up period was the underlying reason for the heterogeneity between studies and thus confirmed the hypothesis that a subgroup analysis based on the follow-up period was appropriate (Figure 5).

Forest plot analysis

For the study group with a follow-up period shorter than 2 months, the HR was 1.22 (95% CI: 0.96–1.56), indicating that the risk of death in current smokers with sepsis was 1.22 times higher than in non-smokers. However, this risk estimate was not significant ($Z=1.66, p=0.10$) (Figure 5). Conversely, for the study group with a follow-up period longer than 2 months, the HR was 2.33 (95% CI: 1.83–2.96).
The effect size was statistically significant ($Z=6.91$, $p<0.00001$), meaning that the mortality rate of current smokers with sepsis was 2.33 times (significantly) higher than that of non-smokers (Figure 5).

**Funnel plot analysis**
A visual evaluation of the funnel plots revealed a symmetrical distribution. Egger’s test showed no significant bias among the studies with a follow-up period shorter than 2 months ($p=0.42$) and studies with a follow-up period longer than 2 months ($p=0.197$).

**DISCUSSION**
Sepsis affects more than 1 million people in the United States each year and has a high mortality rate. The effects of smoking on immune function are well documented, but the overall impact of smoking on the clinical manifestations of sepsis is unclear. In this study, we demonstrated the findings of our first meta-analysis, which was aimed at evaluating the association between smoking and mortality in patients with sepsis. Our findings indicate that smoking increases the mortality risk from sepsis.

The mortality rate in patients with sepsis ranges from 25% to 30%, eventually resulting in considerable healthcare costs$^{36,37}$. Previous studies have shown that smokers have an increased risk of developing sepsis-related organ dysfunction$^{38}$ and septic shock$^{39}$. However, there are few relevant clinical studies, and the data are not comprehensive. This results in insufficient evidence that smoking increases mortality in patients with sepsis. Therefore, it is necessary to understand and explore whether smoking increases the risk of death in patients with sepsis.

Many previous studies have researched the effect of smoking on patients with respiratory infections. Evidence shows that smoking is related to increased mortality in patients with respiratory infections, particularly pneumonia and influenza$^{40,41}$. Furthermore, cigarette smoking markedly induces inflammation and alters immune signaling pathways. Studies have shown that smoking can promote the body’s inflammatory response by increasing the release of pro-inflammatory factors$^{42-44}$. In addition, smoking leads to oxidative stress, which induces systemic inflammation. Smoking is also associated with immunosuppressive effects that reduce a patient’s resistance to infection$^{45}$. Compared with non-smokers, current smokers with sepsis are more likely to require intensive care treatment since their sequential organ failure assessment score, which is used to evaluate the severity of sepsis and predict the outcomes of patients with sepsis, tends to be higher$^{40,46}$. However, the direct relationship between smoking and mortality in patients with sepsis remains unclear.

We also performed a subgroup analysis that considered the duration of the follow-up period.
The mortality rate among smokers was 2.33 times (significantly) higher when compared with non-smokers for patients with a follow-up period longer than 2 months. However, the difference was not significant for patients with a follow-up shorter than 2 months.

Although both early and late stages of sepsis are affected by other health conditions, including chronic diseases, low socioeconomic status and multiple comorbidities, the initial condition of patients with sepsis is unstable and easily deteriorated in the early stage. In addition, current smokers tend to have worse health habits (such as drinking alcohol) and are less likely to participate in influenza and pneumococcal vaccination programs. A few studies have found alcohol abuse to be an independent predictor of mortality in multivariable analyses, although when combined with smoking, it may increase the mortality of sepsis. Our research provides good inspiration for the clinical treatment of patients with sepsis. For patients with sepsis who like to smoke, it is important to prohibit the patient from continuing to smoke during and after treatment.

Strengths and limitations
Our meta-analysis has some limitations that must be acknowledged. The majority of the studies used earlier versions of the sepsis guidelines for grading, and only one of the included studies used the latest version. Our results were based on unadjusted estimates; therefore, future studies should evaluate the impact of other known confounding variables, such as gender, age, body mass index and lifestyle, on the risk of mortality from sepsis among smokers. Furthermore, publication bias could have been introduced by the limited number of studies included, even though our statistical tests showed a low risk of bias. The publication bias could have been increased further by the fact that we included only studies published in English. The number of cigarettes smoked daily may also have an impact on the risk of mortality from smoking. In addition, we did not evaluate former smokers and their risk of mortality from sepsis. As a result, further studies are required. This strategy of grouping the participants into two categories is acceptable, but if options are available to include only non-smoking individuals as non-smokers, that would be more suitable.

However, there are many advantages to this study. Two researchers independently assessed the quality of the included studies using the NOS, and publication bias was evaluated by a funnel plot analysis together with Egger’s test, which provided criteria to evaluate the methodological quality of the studies. To accurately identify the relationship between sepsis and smoking, heterogeneity and sensitivity of the results were analyzed in this study.

CONCLUSIONS
Current smokers with sepsis have a higher risk of death when the follow-up period is longer than 2 months. Although patients with a shorter follow-up period also showed an increased risk of death, the finding was not statistically significant. Thus, current smoking might be a modifiable risk in patients with sepsis. Due to the limitations of this study, further research is required.

REFERENCES
1. Yang JJ, Yu D, Wen W, et al. Tobacco Smoking and Mortality in Asia: A Pooled Meta-analysis. JAMA Netw Open. 2019;2(3):e191474. doi:10.1001/jamanetworkopen.2019.1474
2. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360(9343):1347-1360. doi:10.1016/S0140-6736(02)11403-6
3. World Health Organization. WHO report on the Global Tobacco Epidemic, 2017: Monitoring tobacco use and prevention policies. World Health Organization; 2017. Accessed February 3, 2022. https://apps.who.int/iris/bitstream/handle/10665/255874/9789241512824-eng.pdf?sequence=1&isAllowed=y
4. Jeon J, Holford TR, Levy DT, et al. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Ann Intern Med. 2018;169(10):684-693. doi:10.7326/M18-1250
5. Wheaton AG, Liu Y, Croft JB, et al. Chronic Obstructive Pulmonary Disease and Smoking Status - United States, 2017. MMWR Morb Mortal Wkly Rep. 2019;68(24):533-538. doi:10.15585/mmwr.mm6824a1
6. Cole TB. Smoking Cessation and Reduction of Cardiovascular Disease Risk. JAMA. 2019;322(7):651. doi:10.1001/jama.2019.11166
7. Hartmann-Boyce J, Livingstone-Banks J, Ordonez-Mena JM, et al. Behavioural interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2021;1:CD013229. doi:10.1002/14651858.CD013229.pub2
8. Leite FRM, Nascimento GG, Schuez F, Lopez R. Effect
of Smoking on Periodontitis: A Systematic Review and Meta-regression. Am J Prev Med. 2018;54(6):831-841. doi:10.1016/j.amepre.2018.02.014

9. van der Poll T, van de Veerdonk FL, Sciiluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17(7):407-420. doi:10.1038/nri.2017.36

10. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-211. doi:10.1016/S0140-6736(19)32989-7

11. Ahmadian E, Hosseinian Khaihtib SM, Razi Soofiyani S, et al. Covid-19 and kidney injury: Pathophysiology and molecular mechanisms. Rev Med Virol. 2021;31(3):e2176. doi:10.1002/rmv.2176

12. Abumayyaleh M, Nunez-Gil IJ, El-Battrawy I, et al. Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score. Front Med (Lausanne). 2021;8:728102. doi:10.3389/fmed.2021.728102

13. Abumayyaleh M, Nunez-Gil IJ, El-Battrawy I, et al. Does there exist an obesity paradox in COVID-19? Insights of the international HOPE-COVID-19-registry. Obes Res Clin Pract. 2021;15(3):275-280. doi:10.1016/j.orecp.2021.02.008

14. Yang L, Liu SS, Liu JY, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):128. doi:10.1038/s41392-020-00243-2

15. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med. 2014;42(3): 625-631. doi:10.1097/CCM.0000000000000026

16. Rowe TA, Mckoy JM. Sepsis in Older Adults. Infect Dis Clin North Am. 2017;31(4):731-742. doi:10.1016/j.idc.2017.07.010

17. Mirouse A, Vigneron C, Llitois JF, et al. Sepsis and Cancer: An Interplay of Friends and Foes. Am J Respir Crit Care Med. 2020;202(2):1625-1635. doi:10.1164/rcrm.202004-1116TR

18. Strnad P, Tacke F, Koch A, Trautwein C. Liver - guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol. 2017;14(1):55-66. doi:10.1038/nrgastro.2016.168

19. Poston JT, Koyner JL. Sepsis associated acute kidney injury. BMJ. 2019;364:k4891. doi:10.1136/bmj.k4891

20. Lelubre C, Vincent JL. Mechanisms and treatment of organ failure in sepsis. Nat Rev Nephrol. 2018;14(7):417-427. doi:10.1038/s41581-018-0005-7

21. Huson MA, Grobusch MP, van der Poll T. The effect of HIV infection on the host response to bacterial sepsis. Lancet Infect Dis. 2015;15(1):95-108. doi:10.1016/S1473-3099(14)70917-X

22. Purkayastha A, Sen C, Garcia G, et al. Direct Exposure to SARS-CoV-2 and Cigarette Smoke Increases Infection Severity and Alters the Stem Cell-Derived Airways Repair Response. Cell Stem Cell. 2020;27(6):869-875.e4 doi:10.1016/j.stem.2020.11.010

23. Hamer M, Kivimäki M, Gale CR, Batty GD. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. Brain Behav Immun. 2020;87:184-187. doi:10.1016/j.bbi.2020.05.059

24. Caliri AW, Tommasi S, Besaratinia A. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutat Res Rev Mutat Res. 2021;787:108365. doi:10.1016/j.mrrev.2021.108365

25. Alroumi F, Abdul Azim A, Kergo R, Lei Y, Dargin J. The impact of smoking on patient outcomes in severe sepsis and septic shock. J Intensive Care. 2018;6:42. doi:10.1186/s40560-018-0312-x

26. Kempker JA, Kramer MR, Waller LA, Martin GS. Risk Factors for Septicemia Deaths and Disparities in a Longitudinal US Cohort. Open Forum Infect Dis. 2018;5(12):ofy305. doi:10.1093/ofid/ofy305

27. Pehlivanlar Kucuk M, Kucuk AO, Komsucu O, et al. Effects of personality traits on severity of sepsis. Tuberk Toraks. 2021;69(3):349-359. doi:10.5578/tt.20219707

28. McInnes MDF, Moher D, Thombs BD, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. doi:10.1001/jama.2017.19163

29. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644-1655. doi:10.1378/chest.101.6.1644

30. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;31(4):1250-1256. doi:10.1077/01690546-001978.3B

31. Singer M, Deutschman CS, Seymour CW, et al., The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810. doi:10.1001/jama.2016.0287

32. Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605. doi:10.1007/s10654-010-9491-z

33. Cochran WG. The Combination of Estimates from Different Experiments. Biometrics. 1954;10:1-18. doi:10.2307/3001666

34. Pittet D, Thievent B, Wenzel RP, Li N, Gurman G, Suter PM. Importance of pre-existing comorbidities for prognosis of septicemia in critically ill patients. Intensive Care Med. 1993;19(5):265-272. doi:10.1007/BF01690546

35. Salive ME, Wallace RB, Ostfeld AM, Satterfield S, Havlik
RJ. Risk factors for septicemia-associated mortality in older adults. Public Health Rep. 1993;108(4):447-453. Accessed May 20, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1403407/pdf/pubhealthrep00066-0033.pdf

36. Arefian H, Heublein S, Scherag A, et al. Hospital-related cost of sepsis: A systematic review. J Infect. 2017;74(2):107-117. doi:10.1016/j.jinf.2016.11.006

37. Cohen J, Vincent JL, Adhikari NKJ, et al. Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15(5):581-614. doi:10.1016/S1473-3099(15)70112-X

38. Corbett C, Armstrong MJ, Neuberger J. Tobacco smoking and solid organ transplantation. Transplantation. 2012;94(10):979-987. doi:10.1097/TP.0b013e318263ad5b

39. Iriyama H, Abe T, Kushimoto S, et al. Risk modifiers of acute respiratory distress syndrome in patients with non-pulmonary sepsis: a retrospective analysis of the FORECAST study. J Intensive Care. 2020;8(1). doi:10.1186/s40560-020-0426-9

40. Huttunen R, Laine J, Lumio J, Vuento R, Syrjänen J. Obesity and smoking are factors associated with poor prognosis in patients with bacteremia. BMC Infect Dis. 2007;7:13. doi:10.1186/1471-2334-7-13

41. Pirie K, Petö R, Reeves GK, Green J, Beral V; Million Women Study Collaborators. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet. 2013;381(9861):133-141. doi:10.1016/S0140-6736(12)61720-6

42. Elisia I, Lam V, Cho B, et al. The effect of smoking on chronic inflammation, immune function and blood cell composition. Sci Rep. 2020;10(1):19480. doi:10.1038/s41598-020-76556-7

43. Nii T, Kuzuya K, Kabata D, et al. Crosstalk between tumor necrosis factor-alpha signaling and aryl hydrocarbon receptor signaling in nuclear factor -kappa B activation: A possible molecular mechanism underlying the reduced efficacy of TNF-inhibitors in rheumatoid arthritis by smoking. J Autoimmun. 2019;98:95-102. doi:10.1016/j.jaut.2018.12.004

44. Sliwinska-Mosson M, Marek G, Grzebieniak Z, Milnerowicz H. Relationship between somatostatin and interleukin-6: A cross-sectional study in patients with acute pancreatitis. Pancreatology. 2018;18(8):885-891. doi:10.1016/j.pan.2018.09.013

45. McGrath-Morrow SA, Gorzkowski J, Groner JA, et al. The Effects of Nicotine on Development. Pediatrics. 2020;145(3):e20191346. doi:10.1542/peds.2019-1346

46. Monteiro AC, Suri R, Emeruwa IO, et al. Obesity and smoking as risk factors for invasive mechanical ventilation in COVID-19: A retrospective, observational cohort study. PLoS One. 2020;15(12):e0238552. doi:10.1371/journal.pone.0238552

47. Bello S, Menéndez R, Antoni T. Tobacco Smoking Increases the Risk for Death From Pneumococcal Pneumonia. Chest. 2014;146(4):1029-1037. doi:10.1378/chest.13-2853

48. Bobo JK, Husten C. Sociocultural influences on smoking and drinking. Alcohol Res Health. 2000;24(4):225-32. doi:10.1093/alcald/35.1.104

49. Pearson WS, Dube SR, Ford ES, Mokdad AH. Influenza and pneumococcal vaccination rates among smokers: data from the 2006 Behavioral Risk Factor Surveillance System. Prev Med. 2009;48(2):180-183. doi:10.1016/j.ypmed.2008.11.001